Skip to content

abc

NO NEWS IS GOOD NEWS

More relief with the Powerful Consistency of KISQALI*(1)

Consistent results across a broad range of HR+/HER2- eligible patients with statistically significant improvements in iDFS (EBC), PFS and OS (ABC).*(1)

* vs AI in the NATALEE study and ET in the MONALEESA studies.(1)
1. KISQALI (ribociclib). Summary of Product Characteristics.

Proven efficacy

Fictional portrait of a smilling black postmenopausal woman representing the MONALEESA-2 breast cancer study design.

MONALEESA-2

KISQALI + AI in 1L postmenopausal patients

MONALEESA-2
1L in postmenopausal patients: KISQALI + AI significantly increased mOS benefit vs AI alone.(1)
Discover the results
Fictional portrait of a smilling Middle Eastern postmenopausal woman representing the MONALEESA-3 advanced breast cancer clinical trial.

MONALEESA-3

KISQALI + fulvestrant in 1L/2L postmenopausal patients

MONALEESA-3
1L in postmenopausal patients: KISQALI + fulvestrant significantly increased mOS benefit vs fulvestrant alone.(1)
Discover the results
Fictional portrait of a smiling asian premenopausal woman used for MONALEESA-7 breast cancer study design.

MONALEESA-7

KISQALI + ET in 1L premenopausal patients

MONALEESA-7
1L in premenopausal patients: KISQALI the first and only CDK4/6i to achieve 5-year mOS.(1)
Discover the results

Give more of your patients
news worth sharing

In HR+/HER2- ABC, KISQALI + ET:

Overall survival (OS)

The only CDK4/6i with statistically significant 1L m0S benefit across three phase III trials†(1-4)

Quality of life (QOL)

Consistently preserves QOL across phase III trials and achieved a time to deterioration (TTD) ≥10% across trials(5-8)

Safety profile

A well-established safety profile consistent across a broad range of patients(9-12)

For Healthcare Professionals Outside the US

KISQALI is indicated in the EU for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

KISQALI in combination with an aromatase inhibitor is indicated in the EU for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

City river view encouraging healthcare professionals to access country-specific NovartisPro information.

Visit your local HCP portal for further country specific information

This website is intended for Health Care Professionals (HCPs) outside the US and Switzerland. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information. By clicking continue you are confirming that you are an HCP.

Disclaimer: This is an international website for KISQALI® (ribociclib) and is intended for Healthcare Professionals outside the US. The information on the site is not country-specific and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local representative for local prescribing information via novartis.com/contacts.

Fictional healthcare professional and patient.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
Produced and funded by Novartis.